查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1813857

肺癌診斷市場規模、佔有率和趨勢分析報告：按類型、測試、最終用途、地區和細分市場預測，2025-2033 年

Lung Cancer Diagnostics Market Size, Share & Trends Analysis Report By Type (Small Cell Lung Cancer, Non-Small Cell Lung Cancer), By Test (CA Tests, HER2 Tests, ALK Tests), By End Use, Region And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

肺癌診斷市場摘要

預計 2024 年全球肺癌診斷市場價值將達到 123.7 億美元，到 2033 年將達到 233.1 億美元，2025 年至 2033 年的複合年成長率為 7.5%。

該市場包括旨在促進肺癌早期發現和準確分類的診斷技術。

各種診斷方法，包括影像技術、分子檢測和基於切片檢查的評估，都被用於支持臨床決策。人們越來越重視識別可用於個人化醫療和標靶治療的基因變異，這推動了先進分子診斷和液態切片方法的應用。

人們日益意識到早期癌症檢測的重要性，診斷影像系統和次世代定序儀平台的不斷發展，這些因素正在塑造市場格局。基於人工智慧的影像分析的整合以及就地檢驗解決方案的擴展，也提高了診斷準確性並縮短了周轉時間。此外，篩檢項目的增加（尤其是在高風險族群中），以及衛生當局的支持性舉措，正在加速對創新診斷工具的需求。這些因素正在推動全球肺癌診斷產業的成長。

在全球範圍內，肺癌是男性第二大常見癌症。然而，在一些國家，肺癌是癌症相關死亡的重要原因。常見症狀包括咳血、咳嗽以及體重減輕、食慾不振等全身性症狀，這些症狀會增加包括癌症在內的慢性疾病的可能性。世界衛生組織估計，肺癌每年導致約180萬人死亡。男性過度吸菸現象十分普遍，菸草中含有約7,000種化學物質，其中50多種已知會致癌。因此，過量吸菸和吸菸可能是肺癌篩檢和診斷的重要因素。

近年來，無論是否吸煙，慢性肺癌患者的數量都顯著增加。例如，小細胞肺癌 (SCLC) 患者可能曾經吸煙，也可能從未吸煙。然而，15% 至 20% 的患者曾接觸過二手菸或被動吸菸。除了吸菸之外，氡暴露、石棉、遺傳、空氣污染和飲食因素也會導致患者罹患慢性肺癌。遺傳和石棉會增加患者罹患癌症的可能性。

整體而言，全球肺癌診斷產業正朝著更精準、更快速、侵入性更低的方向發展。人工智慧、NGS 和液態切片解決方案的持續整合正在簡化臨床工作流程，並實現更早的檢測，這對於改善患者預後至關重要。對創新技術的投資不斷增加以及篩檢舉措的不斷擴展，預計將進一步增強整個醫療保健系統的診斷能力。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章市場變數、趨勢和範圍

  • 市場區隔和範圍
  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
  • 市場促進因素
    • 肺癌發生率上升
    • 生物標記和分子檢測的採用率不斷提高
    • 影像和液態生物檢體的技術進步
  • 市場限制因素分析
    • 進階診斷測試高成本
    • 新興國家的基礎建設限制
  • 商業環境分析
    • 依因素（政治/法律、經濟/技術）進行 SWOT 分析
    • 波特五力分析
    • COVID-19影響分析

第4章 業務類型分析

  • 肺癌診斷市場：類型變異分析
  • 非小細胞肺癌
  • 小細胞肺癌

第5章 透過測試進行業務分析

  • 肺癌診斷市場：測試波動分析
  • CA 檢查
  • HER2檢測
  • ALK偵測
  • 血管新生抑制劑
  • EGFR突變檢測
  • KRAS突變檢測

第6章 以最終用途分類的業務分析

  • 肺癌診斷市場：最終用途差異分析
  • 醫院
  • 研究所
  • 其他

第7章 區域業務分析

  • 2023年及2033年肺癌診斷市佔率（按地區）
  • 北美洲
    • 2021-2033年北美肺癌診斷市場
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2021-2033年歐洲肺癌診斷市場
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 2021-2033年亞太地區肺癌診斷市場
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 拉丁美洲肺癌診斷市場，2021-2033年
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 中東和非洲肺癌診斷市場，2021-2033年
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭態勢

  • 參與企業概況
  • 財務表現
  • 參與企業
    • 市場領導者
    • 肺癌診斷市場佔有率分析（2023年）
    • 公司簡介
    • 戰略地圖
Product Code: 978-1-68038-888-6

Lung Cancer Diagnostics Market Summary

The global lung cancer diagnostics market size was estimated at USD 12.37 billion in 2024 and is projected to reach USD 23.31 billion by 2033, growing at a CAGR of 7.5% from 2025 to 2033. The market encompasses diagnostic technologies designed to facilitate the early detection and accurate classification of lung cancer, which remains one of the leading causes of cancer-related mortality worldwide.

A broad range of diagnostic modalities, such as imaging techniques, molecular tests, and biopsy-based assessments, are employed to support clinical decision-making. The adoption of advanced molecular diagnostics and liquid biopsy methods is gaining traction, driven by the rising focus on personalized medicine and the identification of actionable genetic mutations for targeted therapy.

Growing awareness about the importance of early cancer detection, coupled with ongoing developments in imaging systems and next-generation sequencing platforms, is shaping the market landscape. The integration of AI-based image analysis and the expansion of point-of-care testing solutions are also improving diagnostic accuracy and reducing turnaround times. In addition, increased screening programs, particularly in high-risk populations, and supportive initiatives by health authorities are accelerating the demand for innovative diagnostic tools. These factors contribute to the growth of the global lung cancer diagnostics industry.

Worldwide, lung cancer is the second leading and most occurring cancer in men. However, in several countries, lung cancer has become one of the prominent causes of cancer-related deaths. The common symptoms include hemoptysis, cough, or systemic symptoms such as weight loss or anorexia that increase the chances of developing chronic conditions, including cancer. The WHO estimates around 1.80 million deaths due to lung cancer worldwide annually. Excessive smoking habits are highly prevalent in men, and tobacco exposure contains around 7,000 chemicals, with more than 50 known cancer-causing chemicals. Therefore, excessive tobacco consumption and smoking are likely to be significant factors for lung screening and diagnostics.

Over the past few years, there has been a prominent rise in patients with chronic lung cancers irrespective of smoking. For instance, patients with small-cell lung cancer (SCLC) may or may not have a smoking history. However, 15 to 20 percent of patients are exposed to secondhand or passive smoking. Besides smoking, other factors such as radon exposure, asbestos, genetics, air pollution, and dietary factors develop chronic conditions in patients. Genetics and asbestos account for a high probability of developing cancerous conditions in patients.

Overall, the global lung cancer diagnostics industry is progressing toward more precise, faster, and less invasive diagnostic approaches. Continuous integration of AI, NGS, and liquid biopsy solutions is streamlining clinical workflows and enabling early detection, which is essential for improving patient outcomes. Growing investments in innovative technologies and the expansion of screening initiatives are expected to further strengthen diagnostic capabilities across healthcare systems.

Global Lung Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the lung cancer diagnostics market report based on type, test, end use, and region:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Non-small cell lung cancer
  • Small cell lung cancer
  • Test Outlook (Revenue, USD Million, 2021 - 2033)
  • CA test
  • HER2 test
  • ALK test
  • Angiogenesis Inhibitors
  • EGFR Mutation test
  • KRAS Mutation test
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Laboratories
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation
    • 1.1.1. Market Definitions
  • 1.2. Objectives
    • 1.2.1. Objective - 1
    • 1.2.2. Objective - 2
    • 1.2.3. Objective - 3
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. Gvr's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers
    • 3.4.1. Rising Lung Cancer Incidence
    • 3.4.2. Growing Adoption of Biomarker and Molecular Testing
    • 3.4.3. Technological Advancements in Imaging and Liquid Biopsy
  • 3.5. Market Restraint Analysis
    • 3.5.1. High Cost of Advanced Diagnostic Tests
    • 3.5.2. Limited Infrastructure in Emerging Economies
  • 3.6. Business Environment Analysis
    • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.6.2. Porter's Five Forces Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Type Business Analysis

  • 4.1. Lung Cancer Diagnostics Market: Type Movement Analysis
  • 4.2. Non-small Cell Lung Cancer
    • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3. Small Cell Lung Cancer
    • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Test Business Analysis

  • 5.1. Lung Cancer Diagnostics Market: Test Movement Analysis
  • 5.2. CA Test
    • 5.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3. HER2 Test
    • 5.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. ALK Test
    • 5.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Angiogenesis Inhibitors
    • 5.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. EGFR Mutation test
    • 5.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. KRAS Mutation test
    • 5.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. End Use Business Analysis

  • 6.1. Lung Cancer Diagnostics Market: End Use Movement Analysis
  • 6.2. Hospitals
    • 6.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3. Laboratories
    • 6.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Others
    • 6.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Lung Cancer Diagnostics Market Share By Region, 2023 & 2033
  • 7.2. North America
    • 7.2.1. North America Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Target Disease Prevalence
      • 7.2.2.3. Competitive Scenario
      • 7.2.2.4. Regulatory Framework
      • 7.2.2.5. Reimbursement Scenario
      • 7.2.2.6. U.S. Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Target Disease Prevalence
      • 7.2.3.3. Competitive Scenario
      • 7.2.3.4. Regulatory Framework
      • 7.2.3.5. Reimbursement Scenario
      • 7.2.3.6. Canada Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Key Country Dynamics
      • 7.2.4.2. Target Disease Prevalence
      • 7.2.4.3. Competitive Scenario
      • 7.2.4.4. Regulatory Framework
      • 7.2.4.5. Reimbursement Scenario
      • 7.2.4.6. Mexico Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.3.2. Germany
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Target Disease Prevalence
      • 7.3.2.3. Competitive Scenario
      • 7.3.2.4. Regulatory Framework
      • 7.3.2.5. Reimbursement Scenario
      • 7.3.2.6. Germany Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.3.3. UK
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Target Disease Prevalence
      • 7.3.3.3. Competitive Scenario
      • 7.3.3.4. Regulatory Framework
      • 7.3.3.5. Reimbursement Scenario
      • 7.3.3.6. UK Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Target Disease Prevalence
      • 7.3.4.3. Competitive Scenario
      • 7.3.4.4. Regulatory Framework
      • 7.3.4.5. Reimbursement Scenario
      • 7.3.4.6. France Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Target Disease Prevalence
      • 7.3.5.3. Competitive Scenario
      • 7.3.5.4. Regulatory Framework
      • 7.3.5.5. Reimbursement Scenario
      • 7.3.5.6. Italy Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Target Disease Prevalence
      • 7.3.6.3. Competitive Scenario
      • 7.3.6.4. Regulatory Framework
      • 7.3.6.5. Reimbursement Scenario
      • 7.3.6.6. Spain Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Target Disease Prevalence
      • 7.3.7.3. Competitive Scenario
      • 7.3.7.4. Regulatory Framework
      • 7.3.7.5. Reimbursement Scenario
      • 7.3.7.6. Denmark Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Target Disease Prevalence
      • 7.3.8.3. Competitive Scenario
      • 7.3.8.4. Regulatory Framework
      • 7.3.8.5. Reimbursement Scenario
      • 7.3.8.6. Sweden Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Target Disease Prevalence
      • 7.3.9.3. Competitive Scenario
      • 7.3.9.4. Regulatory Framework
      • 7.3.9.5. Reimbursement Scenario
      • 7.3.9.6. Norway Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Competitive Scenario
      • 7.4.2.4. Regulatory Framework
      • 7.4.2.5. Reimbursement Scenario
      • 7.4.2.6. Japan Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Competitive Scenario
      • 7.4.3.4. Regulatory Framework
      • 7.4.3.5. Reimbursement Scenario
      • 7.4.3.6. China Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Competitive Scenario
      • 7.4.4.4. Regulatory Framework
      • 7.4.4.5. Reimbursement Scenario
      • 7.4.4.6. India Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Target Disease Prevalence
      • 7.4.5.3. Competitive Scenario
      • 7.4.5.4. Regulatory Framework
      • 7.4.5.5. Reimbursement Scenario
      • 7.4.5.6. South Korea Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Target Disease Prevalence
      • 7.4.6.3. Competitive Scenario
      • 7.4.6.4. Regulatory Framework
      • 7.4.6.5. Reimbursement Scenario
      • 7.4.6.6. Australia Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Target Disease Prevalence
      • 7.4.7.3. Competitive Scenario
      • 7.4.7.4. Regulatory Framework
      • 7.4.7.5. Reimbursement Scenario
      • 7.4.7.6. Thailand Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Competitive Scenario
      • 7.5.2.4. Regulatory Framework
      • 7.5.2.5. Reimbursement Scenario
      • 7.5.2.6. Brazil Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Competitive Scenario
      • 7.5.3.4. Regulatory Framework
      • 7.5.3.5. Reimbursement Scenario
      • 7.5.3.6. Argentina Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Competitive Scenario
      • 7.6.2.4. Regulatory Framework
      • 7.6.2.5. Reimbursement Scenario
      • 7.6.2.6. South Africa Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Competitive Scenario
      • 7.6.3.4. Regulatory Framework
      • 7.6.3.5. Reimbursement Scenario
      • 7.6.3.6. Saudi Arabia Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Competitive Scenario
      • 7.6.4.4. Regulatory Framework
      • 7.6.4.5. Reimbursement Scenario
      • 7.6.4.6. UAE Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Competitive Scenario
      • 7.6.5.4. Regulatory Framework
      • 7.6.5.5. Reimbursement Scenario
      • 7.6.5.6. Kuwait Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant's overview
  • 8.2. Financial performance
  • 8.3. Participant categorization
    • 8.3.1. Market Leaders
    • 8.3.2. Lung Cancer Diagnostics Market Share Analysis, 2023
    • 8.3.3. Company Profiles
      • 8.3.3.1. F. Hoffmann-La Roche Ltd
        • 8.3.3.1.1. Company Overview
        • 8.3.3.1.2. Financial Performance
        • 8.3.3.1.3. Product Benchmarking
        • 8.3.3.1.4. Strategic Initiatives
      • 8.3.3.2. Thermo Fisher Scientific
        • 8.3.3.2.1. Company Overview
        • 8.3.3.2.2. Financial Performance
        • 8.3.3.2.3. Product Benchmarking
        • 8.3.3.2.4. Strategic Initiatives
      • 8.3.3.3. Illumina Inc.
        • 8.3.3.3.1. Company Overview
        • 8.3.3.3.2. Financial Performance
        • 8.3.3.3.3. Product Benchmarking
        • 8.3.3.3.4. Strategic Initiatives
      • 8.3.3.4. Agilent Technologies
        • 8.3.3.4.1. Company Overview
        • 8.3.3.4.2. Financial Performance
        • 8.3.3.4.3. Product Benchmarking
        • 8.3.3.4.4. Strategic Initiatives
      • 8.3.3.5. QIAGEN
        • 8.3.3.5.1. Company Overview
        • 8.3.3.5.2. Financial Performance
        • 8.3.3.5.3. Product Benchmarking
        • 8.3.3.5.4. Strategic Initiatives
      • 8.3.3.6. Abbott
        • 8.3.3.6.1. Company Overview
        • 8.3.3.6.2. Financial Performance
        • 8.3.3.6.3. Product Benchmarking
        • 8.3.3.6.4. Strategic Initiatives
      • 8.3.3.7. Bio-Rad
        • 8.3.3.7.1. Company Overview
        • 8.3.3.7.2. Financial Performance
        • 8.3.3.7.3. Product Benchmarking
        • 8.3.3.7.4. Strategic Initiatives
      • 8.3.3.8. Neogenomics Laboratories
        • 8.3.3.8.1. Company Overview
        • 8.3.3.8.2. Financial Performance
        • 8.3.3.8.3. Product Benchmarking
        • 8.3.3.8.4. Strategic Initiatives
      • 8.3.3.9. bioMerieux
        • 8.3.3.9.1. Company Overview
        • 8.3.3.9.2. Financial Performance
        • 8.3.3.9.3. Product Benchmarking
        • 8.3.3.9.4. Strategic Initiatives
      • 8.3.3.10. Myriad Genetics, Inc.
        • 8.3.3.10.1. Company Overview
        • 8.3.3.10.2. Financial Performance
        • 8.3.3.10.3. Product Benchmarking
        • 8.3.3.10.4. Strategic Initiatives
    • 8.3.4. Strategy Mapping
      • 8.3.4.1. Expansion
      • 8.3.4.2. Acquisition
      • 8.3.4.3. Collaborations
      • 8.3.4.4. Disease Type/Drug Class Launch
      • 8.3.4.5. Partnerships
      • 8.3.4.6. Others

List of Tables

  • TABLE 1 Lung Cancer Diagnostics Market - Industry Snapshot & Key Buying Criteria, 2021 - 2033
  • TABLE 2 Global Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 3 Global Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 4 Global Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 5 Global Lung Cancer Diagnostics Market, by region, 2021 - 2033 (USD Million)
  • TABLE 6 Lung Cancer Diagnostics- Key market driver analysis
  • TABLE 7 Lung Cancer Diagnostics- Key market restraint analysis
  • TABLE 8 North America Lung Cancer Diagnostics Market, by country, 2021 - 2033 (USD Million)
  • TABLE 9 North America Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 10 North America Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 11 North America Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 12 U.S. Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 13 U.S. Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 14 U.S. Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 15 Canada Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 16 Canada Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 17 Canada Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 18 Mexico Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 19 Mexico Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 20 Mexico Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 21 Europe Lung Cancer Diagnostics Market, by country, 2021 - 2033 (USD Million)
  • TABLE 22 Europe Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 23 Europe Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 24 Europe Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 25 Germany Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 26 Germany Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 27 Germany Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 28 UK Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 29 UK Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 30 UK Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 31 France Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 32 France Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 33 France Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 34 Italy Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 35 Italy Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 36 Italy Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 37 Spain Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 38 Spain Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 39 Spain Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 40 Denmark Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 41 Denmark Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 42 Denmark Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 43 Sweden Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 44 Sweden Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 45 Sweden Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 46 Norway Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 47 Norway Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 48 Norway Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 49 Asia Pacific Lung Cancer Diagnostics Market, by country, 2021 - 2033 (USD Million)
  • TABLE 50 Asia Pacific Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 51 Asia Pacific Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 52 Asia Pacific Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 53 Japan Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 54 Japan Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 55 Japan Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 56 China Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 57 China Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 58 China Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 59 India Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 60 India Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 61 India Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 62 Australia Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 63 Australia Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 64 Australia Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 65 South Korea Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 66 South Korea Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 67 South Korea Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 68 Thailand Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 69 Thailand Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 70 Thailand Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 71 Latin America Lung Cancer Diagnostics Market, by country, 2021 - 2033 (USD Million)
  • TABLE 72 Latin America Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 73 Latin America Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 74 Latin America Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 75 Brazil Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 76 Brazil Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 77 Brazil Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 78 Argentina Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 79 Argentina Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 80 Argentina Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 81 MEA Lung Cancer Diagnostics Market, by country, 2021 - 2033 (USD Million)
  • TABLE 82 MEA Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 83 MEA Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 84 MEA Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 85 South Africa Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 86 South Africa Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 87 South Africa Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 88 Saudi Arabia Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 89 Saudi Arabia Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 90 Saudi Arabia Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 91 UAE Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 92 UAE Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 93 UAE Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 94 Kuwait Lung Cancer Diagnostics Market, by type, 2021 - 2033 (USD Million)
  • TABLE 95 Kuwait Lung Cancer Diagnostics Market, by test, 2021 - 2033 (USD Million)
  • TABLE 96 Kuwait Lung Cancer Diagnostics Market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • FIG. 1 Lung Cancer Diagnostics Market Segmentation
  • FIG. 2 Global Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 3 Lung Cancer Diagnostics Market Dynamics
  • FIG. 4 Key Opportunities Prioritized, 2018
  • FIG. 5 Lung Cancer Diagnostics Market - Porter's Analysis
  • FIG. 6 Lung Cancer Diagnostics Market - PESTEL Analysis
  • FIG. 7 Lung Cancer Diagnostics Revenue Share, By Type, 2023 & 2033
  • FIG. 8 Non-small cell lung cancer Market, 2021 - 2033 (USD Million)
  • FIG. 9 Small cell lung cancer Market, 2021 - 2033 (USD Million)
  • FIG. 10 Lung Cancer Diagnostics Revenue Share, By Test, 2023 & 2033
  • FIG. 11 CA test Market, 2021 - 2033 (USD Million)
  • FIG. 12 HER2 test Market, 2021 - 2033 (USD Million)
  • FIG. 13 ALK test Market, 2021 - 2033 (USD Million)
  • FIG. 14 Angiogenesis Inhibitors Market, 2021 - 2033 (USD Million)
  • FIG. 15 EGFR Mutation Test Market, 2021 - 2033 (USD Million)
  • FIG. 16 KRAS Mutation Test Market, 2021 - 2033 (USD Million)
  • FIG. 17 Lung Cancer Diagnostics Revenue Share, By End Use, 2023 & 2033
  • FIG. 18 Hospitals Market, 2021 - 2033 (USD Million)
  • FIG. 19 Laboratories Market, 2021 - 2033 (USD Million)
  • FIG. 20 Others Market, 2021 - 2033 (USD Million)
  • FIG. 21 Lung Cancer Diagnostics Revenue Share, By Region, 2023 & 2033
  • FIG. 22 North America Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 23 U.S. Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 24 Canada Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 25 Mexico Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 26 Europe Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 27 Germany Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 28 UK Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 29 France Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 30 Italy Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 31 Spain Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 32 Denmark Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 33 Sweden Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 34 Norway Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 35 Asia Pacific Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 36 Japan Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 37 China Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 38 India Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 39 Australia Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 40 South Korea Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 41 Thailand Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 42 Latin America Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 43 Brazil Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 44 Argentina Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 45 MEA Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 46 South Africa Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 47 Saudi Arabia Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 48 UAE Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)
  • FIG. 49 Kuwait Lung Cancer Diagnostics Market, 2021 - 2033 (USD Million)